Furthermore, promising outcomes (ORR, 67.5%; progression free survival, 7.5 months) were reported in a phase I trial (27) of axitinib plus toripalimab (an anti-PD-1 antibody) in patients with advanced mucosal melanoma, who reacted poorly to anti-PD-1 monotherapy. The gene discussed is PDCD1; the disease is melanoma.